VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)

40 filings reported holding VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7.11M shares of 16.7M outstanding shares and own 42.68% of the company stock.
Largest 10 shareholders include EVENTIDE ASSET MANAGEMENT, LLC (1.39M shares), CITADEL ADVISORS LLC (1.1M shares), ACORN CAPITAL ADVISORS, LLC (786K shares), DAFNA Capital Management LLC (636K shares), VANGUARD GROUP INC (476K shares), Exome Asset Management LLC (463K shares), Palo Alto Investors LP (445K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (344K shares), Patient Square Capital LP (257K shares), and Parkman Healthcare Partners LLC (218K shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.